AsthmaPhase 1NCT03060044
Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler and Seretide Diskus
A Phase 1 study testing Salmeterol/fluticasone Easyhaler, Salmeterol/fluticasone Easyhaler with charcoal and Seretide Diskus in people with Asthma, run by Orion Corporation, Orion Pharma at 1 site in Finland.
Trial summary
Pharmacokinetic study comparing Salmeterol/fluticasone Easyhaler products and Seretide Diskus 50/500 µg/inhalation; a randomised, open, single centre, single dose, crossover study in healthy subjects Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Asthma
- What is being tested?
- Salmeterol/fluticasone Easyhaler, Salmeterol/fluticasone Easyhaler with charcoal and Seretide Diskus
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 64 participants
- Where
- 1 siteFinland
- Study dates
- Jul 2016to Nov 2016
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- written informed consent obtained
- good general health ascertained by detailed medical history, and laboratory and physical examinations
Who cannot join
- evidence of a clinically significant cardiovascular, renal, hepatic, hematological, GI, pulmonary, metabolic-endocrine, neurological or psychiatric disease within the previous 2 years
- any condition requiring concomitant treatment (including vitamins and herbal products)or likely to need any concomitant treatment during the study. as an exception paracetamol and ibuprofen for occasional pain are allowed
- known hypersensitivity to the active substance(s) or the excipient (lactose, which contains small amounts of milk protein) of the drug
- pregnant or lactating females
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler Products and Seretide Diskus 50/500 µg/Inhalation: A Randomised, Open, Single Centre, Single Dose, Crossover Study in Healthy Subjects
Pharmacokinetic study comparing Salmeterol/fluticasone Easyhaler products and Seretide Diskus 50/500 µg/inhalation; a randomised, open, single centre, single dose, crossover study in healthy subjects
- Conditions
- Asthma
- Being tested
- Salmeterol/fluticasone Easyhaler, Salmeterol/fluticasone Easyhaler with charcoal, Seretide Diskus, Seretide Diskus with charcoal
- Medical subject headings
- Asthma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Salmeterol/fluticasone EasyhalerDrug
Salmeterol/fluticasone Easyhaler with charcoalDrug
Seretide DiskusDrug
Seretide Diskus with charcoalDrug
| Study group | Role | What they receive |
|---|---|---|
| Salmeterol/fluticasone Easyhaler | Experimental | single dose of Salmeterol/fluticasone Easyhaler Receives: Drug: Salmeterol/fluticasone Easyhaler |
| Salmeterol/fluticasone Easyhaler with charcoal | Experimental | Single dose of Salmeterol/fluticasone Easyhaler with concomitant charcoal administration Receives: Drug: Salmeterol/fluticasone Easyhaler with charcoal |
| Seretide Diskus | Active comparator | Single dose of Seretide Diskus Receives: Drug: Seretide Diskus |
| Seretide Diskus with charcoal | Active comparator | Single dose of Seretide Diskus with concomitant charcoal administration Receives: Drug: Seretide Diskus with charcoal |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cmax of plasma salmeterol and fluticasone propionate
Measured: 0 hour to 34 hours after study treatment administration
AUCt of plasma salmeterol and fluticasone propionate
Measured: 0 hour to 34 hours after study treatment administration
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Feb 2017
- Study startJul 2016
- Primary completionNov 2016
- Study completionNov 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AsthmaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 64 participants (actual)
Sponsor and investigators
- Lead sponsor
- Orion Corporation, Orion Pharma
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Iissa Kivistö, Study director, Clinical Study director
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03060044
- Sponsor's protocol ID
- 3106010
- Status last verified
- Aug 2016
- First submitted
- 17 Feb 2017
- Last updated
- 3 Mar 2017
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 3 Mar 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler Products and Seretide Diskus 50/500 µg/Inhalation: A Randomised, Open, Single Centre, Single Dose, Crossover Study in Healthy Subjects
- ClinicalTrials.gov ID
- NCT03060044
- Acronym / sponsor ID
- 3106010
- Conditions
- Asthma
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 64 participants (actual)
- Lead sponsor
- Orion Corporation, Orion PharmaIndustry (pharma, biotech, devices)
- Study start
- Jul 2016 (actual)
- Primary completion
- Nov 2016 (actual)
- Study completion
- Nov 2016 (actual)
- First posted
- 23 Feb 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Pharmacokinetic study comparing Salmeterol/fluticasone Easyhaler products and Seretide Diskus 50/500 µg/inhalation; a randomised, open, single centre, single dose, crossover study in healthy subjects
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Salmeterol/fluticasone Easyhaler | Experimental | Drug: Salmeterol/fluticasone Easyhalersingle dose of Salmeterol/fluticasone Easyhaler |
| Salmeterol/fluticasone Easyhaler with charcoal | Experimental | Drug: Salmeterol/fluticasone Easyhaler with charcoalSingle dose of Salmeterol/fluticasone Easyhaler with concomitant charcoal administration |
| Seretide Diskus | Active comparator | Drug: Seretide DiskusSingle dose of Seretide Diskus |
| Seretide Diskus with charcoal | Active comparator | Drug: Seretide Diskus with charcoalSingle dose of Seretide Diskus with concomitant charcoal administration |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- written informed consent obtained
- good general health ascertained by detailed medical history, and laboratory and physical examinations
Key exclusion criteria (4 listed)
- evidence of a clinically significant cardiovascular, renal, hepatic, hematological, GI, pulmonary, metabolic-endocrine, neurological or psychiatric disease within the previous 2 years
- any condition requiring concomitant treatment (including vitamins and herbal products)or likely to need any concomitant treatment during the study. as an exception paracetamol and ibuprofen for occasional pain are allowed
- known hypersensitivity to the active substance(s) or the excipient (lactose, which contains small amounts of milk protein) of the drug
- pregnant or lactating females
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Salmeterol/fluticasone Easyhaler | Drug | Salmeterol/fluticasone Easyhaler |
| Salmeterol/fluticasone Easyhaler with charcoal | Drug | Salmeterol/fluticasone Easyhaler with charcoal |
| Seretide Diskus | Drug | Seretide Diskus |
| Seretide Diskus with charcoal | Drug | Seretide Diskus with charcoal |
Primary outcome
Cmax of plasma salmeterol and fluticasone propionate
Time frame: 0 hour to 34 hours after study treatment administration
AUCt of plasma salmeterol and fluticasone propionate
Time frame: 0 hour to 34 hours after study treatment administration
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Mar 2017.
- Individual participant dataSharing planned: Undecided
Related trials for Asthma
RecruitingPhase 1
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
Asthma
RecruitingPhase 1
A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive
Asthma, Mild Asthma
RecruitingPhase 3
A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma
Asthma Control
Active, not recruitingPhase 2/3
Local Antibiotic Delivery for Community Acquired Pneumonia
Community Acquired Pneumonia (CAP)
RecruitingPhase 2
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
Asthma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Iissa Kivistö study director
Clinical Study director
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Salmeterol/fluticasone Easyhaler, Salmeterol/fluticasone Easyhaler with charcoal and Seretide Diskus in people with Asthma, run by Orion Corporation, Orion Pharma at 1 site in Finland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Mar 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Finland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cmax of plasma salmeterol and fluticasone propionate (time frame: 0 hour to 34 hours after study treatment administration). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Mar 2017.